Aim: Our previous studies have showed that ursodeoxycholic acid (UA) and jasminoidin (JA) effectively reduce cerebral infarct volume in mice. In this study we explored the pure synergistic mechanism of these compounds in treatment of mouse cerebral ischemia, which was defined as synergistic actions specific for phenotype variations after excluding interference from ineffective compounds. Methods: Mice with focal cerebral ischemia were treated with UA, JA or a combination JA and UA (JU). Concha margaritifera (CM) was taken as ineffective compound. Cerebral infarct volume of the mice was determined, and the hippocampi were taken for microarray analysis. Particular signaling pathways and biological functions were enriched based on differentially expressed genes, and corresponding networks were constructed through Ingenuity Pathway Analysis. Results: In phenotype analysis, UA, JA, and JU significantly reduced the ischemic infarct volume with JU being superior to UA or JA alone, while CM was ineffective. As a result, 4 pathways enriched in CM were excluded. Core pathways in the phenotype-positive groups (UA or JA) were involved in neuronal homeostasis and neuropathology. JU-contributing pathways included all UA-contributing and the majority (71.7%) of JA-contributing pathways, and 10 new core pathways whose effects included inflammatory immunity, apoptosis and nervous system development. The functions of JU group included all functions of JA group, the majority (93.1%) of UA-contributing functions, and 3 new core functions, which focused on physiological system development and function. Conclusion: The pure synergism between UA and JA underlies 10 new core pathways and 3 new core functions, which are involved in inflammation, immune responses, apoptosis and nervous system development.
Introduction
A great deal of emphasis has been placed on combination therapy for cerebral ischemia, which is thought to be more effective and has fewer adverse effects than single therapies [1, 2] . Our understanding of the synergistic properties of many current or possible combination therapies has implications for improving therapeutic efficacy and safety [3] . Many experimental methods have been proposed to screen favorable drug combinations using disease-relevant phenotypic assays [4] . Various models and measures, such as the enhanced Petri-Net (EPN) model, Target Inhibition inference using Maximization and Minimization Averaging (TIMMA), additive synergism, Bliss independence, the Chou-Talalay Combination Index, the isobolographic approach, Loewe additivity, and nonlinear blending, have been developed to assess synergistic drug actions [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Considerable research suggests that the synergistic mechanism of drugs is not simply "one target, one pathway". Therefore, it is imperative to turn to network pharmacology by examining the holistic response of phenotyperelated pathways to drug perturbation [15] [16] [17] [18] . However, there is not a clear methodology for screening the core pathways that mediate phenotype variation during global network rewiring. Ways to exclude interference from compounds that are not responsible for outcomes, particularly when the perturbation is from a mixture, are also not well studied. Additional concerns include what role(s) the negative phenotype compounds (compounds that are not responsible for phenotypic variation) play in the full treatment, whether negative phenotype com-www.chinaphar.com Wang PQ et al Acta Pharmacologica Sinica npg pounds affect the core pathway or pure synergism between positive phenotype compounds (compounds contributing to phenotypic variation), and how to investigate the pure synergistic mechanism between positive phenotype ingredients in a mixture. These problems may fundamentally limit the research and design of combination therapies. Thus far, to our knowledge, there is still a lack of research on this topic.
Reverse pharmacology follows the drug-development path from phenotype to target to drug, rather than the classical drug discovery mode. In the reverse pharmacology process, the drug candidates (always effective mixtures) that have known effects on a disease-related phenotype are evaluated for their target-activity, and the active ingredients are extracted. This process may enable more intelligent subsequent screenings of compounds with increased relevant assay readouts [19, 20] and effectively derive core pathways specific for phenotype variations. Accordingly, reverse pharmacology is an important tool for screening and designing combination therapy.
All drugs were injected into the tail vein 1.5 h after the induction of focal cerebral ischemia at 2 mL/kg body weight for once. Our previous studies have shown that ursodeoxycholic acid (UA) and jasminoidin (JA) can significantly reduce ischemic infarct volume [21] [22] [23] [24] [25] . In the current study, we further explored the pure synergistic mechanism of these drugs, excluding interference from any negative phenotype compounds. To accomplish this goal, we compared positive phenotype compounds with negative phenotype compounds, identified differentially expressed genes, constructed networks, and analyzed pathway and function alteration using Ingenuity Pathway Analysis system (IPA, QIAGEN Inc, Dusseldorf, Germany).
Materials and methods

Animal model
Animal experiments were conducted according to the Prevention of Cruelty to Animals Act of 1986 and NIH guidelines for the care and use of laboratory animals for experimental procedures. The animal use protocols were reviewed and approved by the Ethics Review Committee for Animal Experimentation, China Academy of Chinese Medical Sciences. A focal cerebral ischemia-reperfusion model was induced after mice were anesthetized with 2% pentobarbital (4 mg/kg, ip) by middle cerebral artery obstruction, as previously described [26] . The middle cerebral artery received an intraluminal filament and was ligated for 1.5 h and then re-perfused for 24 h. In the sham-operated mice, the external carotid artery (ECA) was surgically prepared for the insertion of the filament, but the filament was not inserted.
Drug administration
The compounds used, ie, UA, JA and concha margaritifera (CM), were standards provided by the National Institutes for Food and Drug Control, the purity were validated by fingerprint chromatographic methodologies. All compounds were dissolved in 0.9% NaCl just before the experiment. All drugs were injected into the tail vein 1.5 h after the induction of focal cerebral ischemia at 2 mL/kg body weight.
A total of 84 male mice (Kunming strain, 3 months old, 38-48 g) were used in this study. In the first experiment, 54 mice were randomly assigned into one of six groups: sham (0.9% NaCl); vehicle (0.9% NaCl); JA (25 mg/mL)-treated; UA (7 mg/mL)-treated; CM (50 mg/mL)-treated; and combination-treated (combination of JA and UA at a 1:1 ratio; the total volume is the same as those of the single compound groups). Nine mice in each group were used for infarction volume tests (phenotype-related analysis) to screen the pharmacological effects of the individual compounds. In the second experiment, 30 mice were divided into 6 groups as in the first experiment and subsequently used for microarray analysis (underlying mechanism analysis). Details of this analysis are discussed in our previous studies [21] [22] [23] [24] [25] [26] .
Phenotype-related screening analysis: calculation of cerebral infarct volume Nine mice in each group underwent phenotype-related analysis and were used to calculate the infarct ratio after the 24 h reperfusion. The brain was removed and cut into five slices in the coronal plane 1, 3, 5, and 7 mm from the prefrontal cortex. The slices were stained with 1% 2,3,5-triphenyl tetrazolium chloride (TTC) in phosphate buffer (0.1 mol/L, pH 7.4) for 30 min at 37 °C in darkness, and then transferred to 10% formalin. Images of these slices were captured by a digital camera (Color CCD camera TP-6001A, Topica Inc, Tokyo, Japan). The area of the infarction region was calculated using a Pathology Image Analysis System (Topica Inc), and the ratio of the infarction volume to the total slice volume was calculated as described in our previous study [21] [22] [23] [24] [25] [26] .
RNA extraction and microarray
The hippocampi of 5 mice in each group were used for underlying mechanism analysis, including RNA isolation and microarray analysis. The cDNA microarray, including 374 cDNA ischemia-related genes, was selected from the Science STKE database. The details of this process are described in our previous studies [21] [22] [23] [24] [25] [26] .
Micro-array data analysis All experimental analyses were performed using the ArrayTrack system (US Food and Drug Administration, Silver Spring, ML, USA). Microarray data analysis was based on the Minimum Information about a Microarray Experiment (MIAME) guidelines and the Micro-array Quality Control (MAQC) project. The results were submitted to the Array Express database. All data were normalized by locally weighted scatter plot smoothing (Lowness) to reduce experimental variability [21] [22] [23] [24] [25] [26] . One-way analysis of variance and significant analysis of micro-arrays were employed to compare the mean numbers of the altered genes between the vehicle and sham, CM and vehicle, UA and CM, JA and CM, and JU and CM groups. To investigate the pure synergistic mechanisms among the effective compounds and exclude any inef-www.nature.com/aps Wang PQ et al Acta Pharmacologica Sinica npg fective compound action, we compared positive phenotype groups (groups shown to be effective in reducing cerebral infarct volume, including UA, JA, JU) with negative phenotype groups (groups shown to be ineffective in reducing cerebral infarct volume, including CM). The phenotype results are shown below. Genes with a P value<0.05 and a >1.5-fold change were selected for further analysis. Additionally, a >1.5-fold increase or <0.5-fold decrease in the expression levels indicated up-or down-regulation, respectively. A list of significantly differentially expressed genes was uploaded to the IPA system (http://www.ingenuity.com/). A cutoff was set to identify molecules whose expression was significantly differentially regulated; these molecules were known as Network Eligible molecules. Networks of Network Eligible Molecules were then algorithmically generated based on their connectivity. Right-tailed Fisher's exact test was used to calculate a P value that determined the probability that each biological function assigned to that network was due to chance alone. The significance of the association among these genes and the canonical pathways was measured in two ways: (1) the ratio of the number of genes from the data set that map to the pathway divided by the total number of genes that map to the canonical pathway; and (2) Fisher's exact test, which was used to calculate a P value that determined the probability that the association between the genes and the canonical pathway could be explained by chance alone. The level of statistical significance was set at P<0.05. Finally, canonical pathways with a P value<0.05 and a >1.5-fold change were screened out and analyzed [21] [22] [23] [24] [25] [26] .
Results
Pharmacological phenotype variation of ischemic infarct volume As described in our previous studies, UA, JA, and JU were effective in reducing the ischemic infarct volume, whereas CM was ineffective. The infarct volume was reduced further by the combination therapy than by each single compound [21] [22] [23] [24] [25] [26] (P<0.05). Thus, we termed the CM group a negative phenotype group, and the other groups were considered positive phenotype groups.
Altered networks and pathways in vehicle
According to the IPA analysis, 66 genes were identified as significantly differentially expressed between the vehicle and sham groups (Supplement Table 1 ). Based on these genes, 2 significant networks were constructed ( Figure 1A ), and 6 significant canonical pathways ( Figure 2A ) and 74 biological functions ( Figure 3A) were identified.
No-prospective changes of networks and pathways in noneffective treated group The IPA analysis identified 30 significantly differentially expressed genes between the CM and vehicle groups. A total of 1 network, 4 canonical pathways (Serotonin Receptor Signaling, Coagulation System, Calcium Signaling, and G-protein Coupled Receptor Signaling), and 39 biological functions were found to be statistically significant (Supplement Table 1 ). To explore the actions of CM targets, we compared the CM and vehicle contributing pathways and found 2 canonical pathways (Serotonin Receptor Signaling and Calcium Signaling), accounting for 50% of the total pathways, and 35 enriched functions, accounting for 89.7% of the total functions that overlapped between the CM and vehicle groups ( Figure 4 ).
Single effective treated groups compared to non-effective group Ten and twenty-two significantly differentially expressed genes were identified in the UA and JA groups, respectively, compared with the CM group. One statistically significant network was constructed in both the UA and JA groups. There were 1 and 59 canonical pathways, and 29 and 53 biological functions were enriched in the UA and JA groups, respectively (Supplement Table 1 , Figure 1-3) . Because of the different phenotypic effects of UA, JA and CM, we eliminated the pathways and functions that overlapped with the CM or vehicle group from the UA or JA group to further uncover the underlying core pathways that exert pharmacological effects. After these pathways and functions were removed, 1 and 57 core pathways remained, 1 and 1 core function remained in the UA and JA groups, respectively (Table 1) .
According to the differentially expressed genes identified by IPA, the enriched biological functions can be divided largely into the following 3 categories: diseases and disorders, molecular and cellular functions, and physiological system development and function. The classifications of the functions in each group are shown in Figure 5 .
Pure pharmacological synergism of combination treatment
The JU group had 29 differentially expressed genes, 1 network, 46 pathways, and 73 functions compared with the CM group (Supplementary Table 1 ). In the JU group, there were 42 core pathways and 4 functions ( Table 1) . A synergistic effect indicates that the efficacy of the combination of drugs is greater than the sum of the efficacies of the individual drugs when administered separately [14] . We created a list of enriched pathways and functions to evaluate the synergism.
When JA was combined with UA, all of UA contributing Genes in uncolored notes were not identified as differentially expressed in our experiment and were integrated into the computationally generated networks based on the evidence stored in the IPA knowledge memory, indicating relevance to this network. Genes in uncolored notes were not identified as differentially expressed in our experiment and were integrated into the computationally generated networks based on the evidence stored in the IPA knowledge memory, indicating relevance to this network. (Figure 4 ). To further derive the pure synergistic mechanism, we removed 2 pathways that overlapped with the CM or vehicle groups ( Table 1) . The remaining 10 core pathways and their actions are shown in Supplement table 2. Notably, the JU group included the entirety of the JA (53) and majority of the UA (27, 93.1% of the 29 functions in the UA group) enriched functions. Interestingly, the overlapping functions in JU (overlapping with UA or JA, 80.8% of all functions in the JU group) cannot fully explain the functions found in the JU group. An additional 14 new functions were identified. The classification of the emerging functions is shown in Figure 5 . To further identify the core functions, 11 functions that overlapped with the CM or vehicle groups (Table 1) were excluded; this analysis left 3 new functions (humoral immune response, tissue development, visual system development and function), all of which belong to physiological system development and function category.
Discussion
When cells respond to stimuli, specifically to effective mixtures or multiple compounds, the molecular network is rewired. This is in contrast to the single target alterations that were previously suggested. Some rewiring, which may be Rewiring that is specific to cerebral ischemia was termed a core mechanism. A core mechanism may contain key synergistic pharmacological mechanisms, particularly when two effective compounds are combined together. This is called pure synergism. A core mechanism cannot be detected by comparing positive phenotype compounds with the vehicle. In the current study, we attempted to eliminate the pathways that were observed in both negative and positive phenotype compounds; the remaining pathways were more specific for phenotype variation.
Non-specific mechanism for phenotype variation in negative phenotype compounds Our previous results indicated that UA and JA could function synergistically in the ischemic hippocampus by regulating multiple targets and numerous cerebral ischemia-related pathways [21] [22] [23] [24] [25] [26] . To investigate whether the negative phenotype compounds play a role in modulating responses to perturbations or network rewiring, we analyzed the alteration in enriched pathways and functions in the negative phenotype compound (CM) group to demonstrate a non-specific pharmacological mechanism for phenotype variation.
In constructing the network according to the pattern of differentially expressed genes in the CM group, HTR2c and HTR3A were indicated as being relevant to the pathogenesis of neurological and psychiatric disorders, such as post-stroke depression [27] [28] [29] [30] . Interestingly, 4 canonical pathways enriched in CM were shown to be associated with neuroregulation or cerebral ischemia [26] [27] [28] [29] [30] [31] . To elucidate the ineffectiveness of CM on phenotype, we conducted an additional analysis and found both Serotonin Receptor Signaling and Calcium Signaling in the vehicle group. This finding may indicate that although CM could modulate neuro-related pathways, pathological processes could not be reversed and the robustness of the cell signaling network could not be rewired by CM. To explain this finding, we hypothesize the following: (1) the 4 pathways may be common pathways instead of core pathways in the cerebral ischemia pathological process and may not be sufficiently critical, specific, or sensitive for reducing ischemia infarction volume; and (2) alternative signaling pathways that compensate for pathways inhibited by CM may be not completely blocked. Furthermore, of the 39 biological functions observed, 35 functions (89.7% of the total) were common to the vehicle group. This result was consistent with pathway analysis. Thus, we concluded that the network conversion caused by CM could not change the inherent properties of cerebral ischemia in the pathological state. This result validated the theory proposed in our previous study, which stated that several pathways should be targeted to optimize therapeutic efficacy [25] .
Core mechanism for phenotype variation in positive phenotype compound We eliminated the pathways from the UA and JA groups that overlapped with the CM group to determine the core pathways and functions of the underlying core mechanism. We chose the top 10 core pathways as examples to elucidate the pharmacological effect of the these groups.
The pathway identified uniquely in the UA group, Huntington's disease signaling, is a pathway involved in neuropathology [32] . Five of the top 10 core pathways in the JA group (50% of the total, ie, Melatonin Signaling, Neuropathic Pain Signaling in Dorsal Horn Neurons, Synaptic Long Term Potentiating, GNRH Signaling, and Sonic Hedgehog Signaling) have been widely reported to be associated with neuronal homeostasis [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] . Little evidence links the remaining 5 identified pathways in the JA group (PPARα/RXRα Activation, Cardiac Hypertrophy Signaling, Molecular Mechanisms of Cancer, Circadian Rhythm Signaling, and the Role of PKR in Interferon Induction and Antiviral Response) with cerebral ischemia processes. For example, few studies have suggested a relationship between cerebral ischemia and PPARα/RXRα Activation, as the function of this pathway involves lipid degradation and obesity [43] . In the JU group, 6 of the top 10 core pathways (Acute Myeloid Leukemia Signaling, Melatonin Signaling, FGF Signaling, Amyotrophic Lateral Sclerosis Signaling, Neuropathic Pain Signaling in Dorsal Horn Neurons, and Synaptic Long Term Potentiation) are widely accepted as involved in neuronal systems [44] [45] [46] [47] [48] [49] . The other 4 of the top 10 core pathways (Molecular Mechanisms of Cancer, CD27 Signaling in Lymphocytes, Cardiac Hypertrophy Signaling, and Cholecystokinin Gastrin-mediated Signaling) showed no clear evidence of their association with cerebral ischemia [50, 51] . We hypothesize that in response to perturbation, cells act as a whole. This leads to the activation of a series of pathways, which may not be limited to those involved in neuropathology. They may also include functions such as metabolic regulation. In addition to these top canonical pathways, many cerebral ischemia-related pathways were identified as core pathways in the positive phenotype groups. For example, P38 MAPK signaling was identified in the JA group, and the nuclear factor-κB (NF-κB) signaling in the JU group is considered a classical inflammatory pathway [52] . The pathways involved may account for the pharmacological phenotype differences between the positive phenotype groups and the CM group. The core mechanisms of positive phenotype groups may primarily be neuronal homeostasis and neuropathology.
Pure synergistic mechanism of pathways and networks convergence To further illuminate the pure synergistic mechanisms, we analyzed JU contributing pathways and found that the pathways may converge, rather than simply stack together in the combination group. The pathways identified in the JU group include specific targets of each single compound. For example, Huntington's disease signaling was identified in the UA and JU groups. Similarly, calcium signaling, PPARα/RXRα activation, IL-10 signaling, and others that were identified in the JA group were also identified in the JU group. This pattern may explain the additive effect of the two compounds. Additionally, it is worth noting that not all of the pathways involved www.chinaphar.com Wang PQ et al Acta Pharmacologica Sinica npg in the JA group were identified in the JU group. For instance, IL-17 signaling, nitric oxide signaling in the cardiovascular system, and IL-6 signaling were observed in the JA group but not in the JU group. This finding led us to speculate that the therapeutic effect of a combination group could include at least a partial effect of the single compounds, rather than simple sum of the pharmacological effects. Moreover, JU may act on more than 10 pathways, which may contribute to the pure synergistic mechanism (Supplement Table 2 ). Some of these new pathways were involved in inflammatory immunity (IL-18 Signaling, Actin Cytoskeleton Signaling, Glucocorticoid Receptor Signaling, Lymphotoxin B Receptor Signaling, and IL-15 Signaling [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] . Therefore, we propose that the pure synergistic mechanism is focused on inflammation, immune responses, apoptosis, and nervous system development ( Figure 6 ). These results validate the theory proposed in our previous study, which stated that the synergistic effects of drug combinations were generated by transmitting drug information, triggering different space-time effects through drug interactions, and generating new phenotypic correlation information sets [23] . Additionally, the detail of overlapping function may provide a possible key to function alteration. The functions of the JU group included all of the functions of the JA group and a majority of the functions of the UA group (Figure 4) . Notably, more than half (8, 57 .1%) of these 14 functions that emerged in the JU group focus on physiological system development and function ( Figure 5 ). Furthermore, 3 core functions (humoral immune response, tissue development, visual system development and function) belong to the physiological system development and function category. Therefore, we infer that modulations in physiological system development and function may be responsible for the increased efficacy of the combined therapy compared with each of the single compounds. Interestingly, these 3 core functions are, to some extent, consistent with the functions regulated by the 10 core pathways referred to in our previous analysis. These results also validate the idea that, when combined, UA and JA integrate and generate more efficacy than a simple additive action, which would suggest and produce additional targeting pathways and biological functions; these additional targets are primarily involved in inflammation, immune responses, apoptosis, and nervous system development.
In the current study, to reveal a pure synergistic mechanism, we integrated phenotype screening and high-throughput genomic analysis to enrich pathways and construct networks. Several features of this approach may contribute substantially to the discovery and analysis of synergism: (1) phenotype screening, a reverse pharmacological method, provides promising access to efficacy for further mechanism exploration; and (2) pure synergism, excluding the impact of ineffective compounds and non-specific pathways for outcomes, identifies core pathways for phenotype variations. As an initial effort for pure synergism, this approach was a qualitative analysis of pathway alterations and network rewiring. Further studies will be devoted to the quantitative analysis of core pathways for further validation.
Conclusion
The pure synergism between UA and JA, which underlie 10 new core pathways and 3 new core functions, is involved in inflammation, immune responses, apoptosis, and nervous system development.
Abbreviation CM, Concha margaritifera; UA, Ursodeoxycholic acid; JA, Jasminoidin; JU, Jasminoidin combined with Ursodeoxycholic acid; STKE, Science signal transduction knowledge environment; ANOVA, Analysis of variance; GnRH, Gonadotropinreleasing hormone; GPCR, G-protein coupled receptor; NF-κB, Nuclear factor-κB; MAPK, Mitogen activated protein kinases; PPARα/RXRα, Peroxisome proliferators-activated receptor α/ retinoid X receptor α; FGF, Fibroblast growth factor; IL, Interleukin.
